Clinical Trial: Sulodexide Treatment in Patients With Dense Deposit Disease

Study Status: Withdrawn
Recruit Status: Withdrawn
Study Type: Interventional

Official Title: Sulodexide Treatment in Patients With Dense Deposit Disease

Brief Summary:

The purpose of this study is to see if a medicine called Sulodexide will help prevent or slow down the progression of Membranoproliferative Glomerulonephritis type II/Dense Deposit Disease. Sulodexide is not yet FDA approved and has not been studied in children.

Study aim/hypotheses: to measure the efficacy of Sulodexide treatment in patients with the above disease/s.

Detailed Summary: Study subjects will be asked to take Sulodexide twice a day. The Sulodexide will be taken in addition to the regular medications the subject is on. There will be no change in these other medications. The subject will also be asked to have blood tests each month to follow kidney function. The frequency of these tests is the normal/standard frequency for persons with MPGN II/DDD and is neither increased nor decreased because of participation in this study. The study will occur over 6 months for each subject.
Sponsor: University of Iowa

Current Primary Outcome: To see if Sulodexide will prevent or slow down the progression of DDD [ Time Frame: 6 mo. ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Normalization of complement function [ Time Frame: 1 year ]

Original Secondary Outcome: Same as current

Information By: University of Iowa

Dates:
Date Received: December 20, 2007
Date Started: December 2007
Date Completion: December 2009
Last Updated: June 10, 2015
Last Verified: June 2015